Page 2096 - Williams Hematology ( PDFDrive )

2070 Part XII: Hemostasis and Thrombosis Chapter 120: Hereditary Qualitative Platelet Disorders 2071

499. Horellou MH, Lecompte T, Lecrubier C, et al: Familial and constitutional bleeding 529. Verhoeven AJ, van Oostrum IE, van Haarlem H, Akkerman JW: Impaired energy
disorder due to platelet cyclo- oxygenase deficiency. Am J Hematol 14:1–9, 1983. metabolism in platelets from patients with Wiskott-Aldrich syndrome. Thromb
500. Rao AK, Koike K, Day HJ, et al: Bleeding disorder associated with albumin-dependent Haemost 61:10–14, 1989.
partial deficiency in platelet thromboxane production. Effect of albumin on arachido- 530. Marone G, Albini F, di Martino L, et al: The Wiskott-Aldrich syndrome: Studies of plate-
nate metabolism in platelets. Am J Clin Pathol 83:687–696, 1985. lets, basophils and polymorphonuclear leucocytes. Br J Haematol 62:737–745, 1986.
501. Roth GJ, Machuga R: Radioimmune assay of human platelet prostaglandin synthetase. 531. Gross BS, Wilde JI, Quek L, et al: Regulation and function of WASp in platelets by the
J Lab Clin Med 99:187–196, 1982. collagen receptor, glycoprotein VI. Blood 94:4166–4176, 1999.
502. Matijevic-Aleksic N, McPhedran P, Wu KK: Bleeding disorder due to platelet pros- 532. Shcherbina A, Rosen FS, Remold-O’Donnell E: Pathological events in platelets of
taglandin H synthase-1 (PGHS-1) deficiency. Br J Haematol 92:212–217, 1996. Wiskott-Aldrich syndrome patients. Br J Haematol 106:875–883, 1999.
503. Defreyn G, Machin SJ, Carreras LO, et al: Familial bleeding tendency with partial plate- 533. Tsuboi S, Nonoyama S, Ochs HD: Wiskott-Aldrich syndrome protein is involved in
let thromboxane synthetase deficiency: Reorientation of cyclic endoperoxide metabo- alphaIIb beta3-mediated cell adhesion. EMBO Rep 7:506–511, 2006.
lism. Br J Haematol 49:29–41, 1981. 534. Rengan R, Ochs HD, Sweet LI, et al: Actin cytoskeletal function is spared, but apoptosis
504. Mestel F, Oetliker O, Beck E, et al: Severe bleeding associated with defective thrombox- is increased, in WAS patient hematopoietic cells. Blood 95:1283–1292, 2000.
ane synthetase. Lancet 1:157, 1980. 535. Falet H, Hoffmeister KM, Neujahr R, Hartwig JH: Normal Arp2/3 complex activation
505. Weiss HJ: Impaired platelet procoagulant mechanisms in patients with bleeding disor- in platelets lacking WASp. Blood 100:2113–2122, 2002.
ders. Semin Thromb Hemost 35:233–241, 2009. 536. Shcherbina A, Cooley J, Lutskiy MI, et al: WASP plays a novel role in regulating platelet
506. Lhermusier T, Chap H, Payrastre B: Platelet membrane phospholipid asymmetry: From responses dependent on alphaIIbbeta3 integrin outside-in signalling. Br J Haematol
the characterization of a scramblase activity to the identification of an essential protein 148:416–427, 2010.
mutated in Scott syndrome. J Thromb Haemost 9:1883–1891, 2011. 537. Kuijpers TW, van de Vijver E, Weterman MA, et al: LAD-1/variant syndrome is caused
507. Weiss HJ, Vicic WJ, Lages BA, Rogers J: Isolated deficiency of platelet procoagulant by mutations in FERMT3. Blood 113:4740–4746, 2009.
activity. Am J Med 67:206–213, 1979. 538. Harris, ES, Smith, TL, Springett, GM, et al: A. Leukocyte adhesion deficiency-I vari-
508. Toti F, Satta N, Fressinaud E, et al: Scott syndrome, characterized by impaired trans- ant syndrome (LAD-Iv, LAD-III): Molecular characterization of the defect in an index
membrane migration of procoagulant phosphatidylserine and hemorrhagic complica- family. Am J Hematol 87: 311–313, 2012.
tions, is an inherited disorder. Blood 87:1409–1415, 1996. 539. Mory A, Feigelson SW, Yarali N, et al: Kindlin-3: A new gene involved in the pathogen-
509. Weiss HJ, Lages B: Platelet prothrombinase activity and intracellular calcium responses esis of LAD-III. Blood 112:2591, 2008.
in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired 540. Svensson L, Howarth K, McDowall A, et al: Leukocyte adhesion deficiency-III is caused
platelet coagulant activity—A comparison with Scott syndrome. Blood 89:1599–1611, by mutations in KINDLIN3 affecting integrin activation. Nat Med 15:306–312, 2009.
1997. 541. Malinin NL, Zhang L, Choi J, et al: A point mutation in KINDLIN3 ablates activation of
510. Dachary-Prigent J, Pasquet JM, Fressinaud E, et al: Aminophospholipid exposure, three integrin subfamilies in humans. Nat Med 15:313–318, 2009.
microvesiculation and abnormal protein tyrosine phosphorylation in the platelets of a 542. Moser M, Nieswandt B, Ussar S, et al: Kindlin-3 is essential for integrin activation and
patient with Scott syndrome: A study using physiologic agonists and local anaesthetics. platelet aggregation. Nat Med 14:325–330, 2008.
Br J Haematol 99:959–967, 1997. 543. Pasvolsky R, Feigelson SW, Kilic SS, et al: A LAD-III syndrome is associated with defec-
511. Zwaal RF, Comfurius P, Bevers EM: Scott syndrome, a bleeding disorder caused by tive expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and
defective scrambling of membrane phospholipids. Biochim Biophys Acta 1636:119–128, platelets. J Exp Med 204:1571–1582, 2007.
2004. 544. Tijssen MR, Cvejic A, Joshi A, et al: Genome-wide analysis of simultaneous GATA1/2,
512. Munnix IC, Harmsma M, Giddings JC, et al: Store-mediated calcium entry in the RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators.
regulation of phosphatidylserine exposure in blood cells from Scott patients. Thromb Dev Cell 20:597–609, 2011.
Haemost 89:687–695, 2003. 545. Rao AK: Spotlight on FLI1, RUNX1 and platelet dysfunction. Blood 122:4004–4006,
513. Solum NO: Procoagulant expression in platelets and defects leading to clinical disor- 2013.
ders. Arterioscler Thromb Vasc Biol 19:2841–2846, 1999. 545A. Songdej N, Rao AK: Hematopoietic transcription factor mutations and inherited platelet
514. Weiss HJ: Scott syndrome-a disorder of platelet coagulant activity. Semin Hematol dysfunction. F1000Prime Reports 7:66, 2015.
31:312–319, 1994. 546. Gerrard JM, Israels ED, Biship AJ, et al: Inherited platelet-storage pool deficiency asso-
515. Sims PJ, Wiedmer T, Esmon CT, et.al: Assembly of the platelet prothrombinase complex ciated with a high incidence of acute myeloid leukaemia. Br J Haematol 79:246–255,
is linked to vesiculation on the platelet plasma membrane. Studies in Scott syndrome: 1991.
An isolated defect in platelet procoagulant activity. J Biol Chem 264:137–148, 1989. 547. Ganly P, Walker LC, Morris CM: Familial mutations of the transcription factor
516. Castaman G, Yu-Feng L, Battistin E, Rodeghiero F: Characterization of a novel bleeding RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia. Leuk Lymphoma
disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle 45:1–10, 2004.
generation. Br J Haematol 96:458–463, 1997. 548. Dowton SB, Beardsley D, Jamison D, et al: Studies of a familial platelet disorder. Blood
517. Albrecht C, McVey JH, Elliott JI, et al: A novel missense mutation in ABCA1 results in 65:557, 1985.
altered protein trafficking and reduced phosphatidylserine translocation in a patient 549. Ho CY, Otterud B, Legare RD, et al: Linkage of a familial platelet disorder with a pro-
with Scott syndrome. Blood 106:542–549, 2005. pensity to develop myeloid malignancies to human chromosome 21q22.1–22.2. Blood
518. Suzuki J, Umeda M, Sims PJ, Nagata S: Calcium-dependent phospholipid scrambling by 87:5218–5224, 1996.
TMEM16F. Nature 468:834–838, 2010. 550. Arepally G, Rebbeck TR, Song W, et al: Evidence for genetic homogeneity in a famil-
519. Weiss HJ: Platelet aggregation, adhesion and adenosine diphosphate release in throm- ial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML).
bopathia (platelet factor 3 deficiency). A comparison with Glanzmann’s thrombasthe- Blood 92:2600–2602, 1998.
nia and von Willebrand’s disease. Am J Med 43:570–578, 1967. 551. Walker LC, Stevens J, Campbell H, et al: A novel inherited mutation of the transcrip-
520. Freson K, De Vos R, Wittevrognel C, et al: The β -tubulin Q43P functional polymor- tion factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid
1
phism reduces the risk of cardiovascular disease in men by modulating platelet func- leukaemia. Br J Haematol 117:878–881, 2002.
tion and structure. Blood 106:2356–2362, 2005. 552. Owen CJ, Toze CL, Koochin A, et al: Five new pedigrees with inherited RUNX1 muta-
521. Navarro-Nunez L, Lozano ML, Rivera J, et al: The association of the beta1-tubulin tions causing familial platelet disorder with propensity to myeloid malignancy. Blood
Q43P polymorphism with intracerebral hemorrhage in men. Haematologica 92: 112:4639–4645, 2008.
513–518, 2007. 553. Sun L, Mao G, Rao AK: Association of CBFA2 mutation with decreased platelet PKC-θ
522. Kunishima S, Kobayashi R, Itoh TJ, et al: Mutation of the beta1-tubulin gene associ- and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphory-
ated with congenital macrothrombocytopenia affecting microtubule assembly. Blood lation: Proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood 103:
113:458–461, 2009. 948–954, 2004.
522A. Berrou, E, Adam, F, Lebret, M et al: Heterogeneity of platelet functional alterations in 554. Rao AK: Inherited platelet function disorders: Overview and disorders of granules,
patients with filamin A mutations. Arterioscler Thromb Vasc Biol 33: e11–8, 2013. secretion, and signal transduction. Hematol Oncol Clin North Am 27:585–611, 2013.
523. Buchbinder D, Nugent DJ, Fillipovich AH: Wiskott-Aldrich syndrome: Diagnosis, cur- 555. Kaur G, Jalagadugula G, Mao G, Rao AK: RUNX1/core binding factor A2 regulates
rent management, and emerging treatments. Appl Clin Genet 7:55–66, 2014. platelet 12-lipoxygenase gene (ALOX12): Studies in human RUNX1 haplodeficiency.
524. Massaad MJ, Ramesh N, Geha RS: Wiskott-Aldrich syndrome: A comprehensive Blood 115:3128–3135, 2010.
review. Ann N Y Acad Sci 1285:26–43, 2013. 556. Jalagadugula G, Mao G, Kaur G, et al: Regulation of platelet myosin light chain (MYL9)
525. Lutskiy MI, Shcherbina A, Bachli ET, et al: WASP localizes to the membrane skeleton of by RUNX1: Implications for thrombocytopenia and platelet dysfunction in RUNX1
platelets. Br J Haematol 139:98–105, 2007. haplodeficiency. Blood 116:6037–6045, 2010.
526. Parkman R, Remold-O’Donnell E, Kenney DM, et al: Surface protein abnormalities 557. Freson K, Devriendt K, Matthijs G, et al: Platelet characteristics in patients with
in lymphocytes and platelets from patients with Wiskott-Aldrich syndrome. Lancet X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 98:
2:1387–1389, 1981. 85–92, 2001.
527. Semple JW, Siminovitch KA, Mody M, et al: Flow cytometric analysis of platelets from 558. Hughan SC, Senis Y, Best D, et al: Selective impairment of platelet activation to collagen
children with the Wiskott-Aldrich syndrome reveals defects in platelet development, in the absence of GATA1. Blood 105:4369–4376, 2005.
activation and structure. Br J Haematol 97:747–754, 1997. 559. Breton-Gorius J, Favier R, Guichard J, et al: A new congenital dysmegakaryopoietic
528. Baldini MG: Nature of the platelet defect in the Wiskott-Aldrich syndrome. Ann N Y thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha-granules and
Acad Sci 201:437–444, 1972. chromosome 11 deletion at 11q23. Blood 85:1805–1814, 1995.

Kaushansky_chapter 120_p2039-2072.indd 2071 9/21/15 2:22 PM